Navigation Links
Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
Date:4/24/2012

FORT LAUDERDALE, Fla., April 24, 2012 /PRNewswire/ -- Nouveau Life Pharmaceuticals, soon to be changed from Hybrid Fuels, Inc., (Pink Sheets: HRID) announced today that it has contracted with an FDA-approved manufacturer to begin production of the first supplement in its New Life Naturals™ product line.

The new supplement – New Life Naturals: For Her Senses™ – is an all-natural product intended to help the nearly 48% of American women suffering with female sexual dysfunction (FSD). Nouveau Life Pharmaceuticals began work on the supplement's formulation in February of this year and finalized the formula ahead of schedule. 

In order to minimize time-to-market and begin production immediately, Nouveau Life opted to partner with an FDA-approved manufacturing facility based in the U.S. The facility is a cGMP (current good manufacturing practice) compliant facility and meets all FDA requirements to manufacture food supplements and over the counter pharmaceuticals.

Nouveau Life expects production of the For Her Senses™ supplement to begin in the coming days and anticipates the nutraceutical will be available for sale to the public within two weeks.

About Hybrid Fuels, Inc.
The company was incorporated in the state of Nevada in 1998 as Polo Equities.  It has primarily been a development stage company with management focused on developing innovative business opportunities and further advancing technologies. 

Forward-Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause future results to differ materially from the forward-looking statements. You should consider these factors in evaluating the statements herein, and not rely on such statements. The forward-looking statements in this release are made as of the date hereof and Hybrid Fuels, Inc. undertakes no obligation to update such statements.

CONTACT:

Nouveau Life Pharmaceuticals, Inc. - 954-903-2993


'/>"/>
SOURCE Nouveau Life Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Webcast Alert: Isis Pharmaceuticals Holds Webcast to Discuss Clinical Development Plans for ISIS-APOCIIIRx
4. Research Alert -- Empire Asset Management Co. Initiates Coverage on Pacira Pharmaceuticals Inc. (NASDAQ: PCRX)
5. Avion Pharmaceuticals, LLC Names Michael Sullivan as new VP, Sales and Marketing
6. Valeant Pharmaceuticals to Announce 2012 First Quarter Results on May 3, 2012
7. Auxilium Pharmaceuticals, Inc. and FCB I LLC Receive Paragraph IV Certification Notice from Watson Laboratories, Inc. for Testim®
8. Duane Morris Litigators Vincent Capuano, Anthony Fitzpatrick and Laura Vogel to Speak at American Conference Institutes Conference on Generic Pharmaceuticals
9. Qualitest Pharmaceuticals Receives FDA Approval for Levetiracetam Oral Solution, 100 mg/mL
10. MAP Pharmaceuticals Provides Update on LEVADEX® Program
11. Gamma Pharmaceuticals, Inc. Announces Distribution Agreement for New York Tri-state Area and Purchase Order for Gamma Energy GEL™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... 28, 2017 Cohen Veterans Bioscience and Early ... of wearable and home sensors for real-time monitoring of ... Foundation, a nonprofit organization focused on disruptive health solutions ... affordable analytical system to record and integrate behavioral, cognitive, ... ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/19/2017)... -- HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy ... team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D ...
Breaking Medicine Technology:
(Date:10/13/2017)... LEXINGTON, Ky. (PRWEB) , ... October 13, 2017 , ... ... MD, MPH to become its next President and Chief Executive Officer, succeeding Dr. James ... and CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end ...
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & ... and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to ... with elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
Breaking Medicine News(10 mins):